A survival score for patients with metastatic spinal cord compression from prostate cancer

D. Rades, S. Douglas, T. Veninga, A. Bajrovic, L. J A Stalpers, P. J. Hoskin, V. Rudat, S. E. Schild

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background. This study aimed to develop and validate a survival scoring system for patients with metastatic spinal cord compression (MSCC) from prostate cancer.Patients and methods. Of 436 patients, 218 patients were assigned to the test group and 218 patients to the validation group. Eight potential prognostic factors (age, performance status, number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, time developing motor deficits) plus the fractionation regimen were retrospectively investigated for associations with survival. Factors significant in the multivariate analysis were included in the survival score. The score for each significant prognostic factor was determined by dividing the 6-month survival rate (%) by 10. The total score represented the sum of the scores for each factor. The prognostic groups of the test group were compared to the validation group.Results. In the multivariate analysis of the test group, performance status, ambulatory status, other bone metastases, visceral metastases, and interval from cancer diagnosis to radiotherapy were significantly associated with survival. Total scores including these factors were 20, 21, 22, 24, 26, 28, 29, 30, 31, 32, 33, 35, 37, or 39 points. In the test group, the 6-month survival rates were 6.5% for 20-24 points, 44.6% for 26-33 points, and 95.8% for 35-39 points (p < 0.0001). In the validation group, the 6-month survival rates were 7.4%, 45.4%, and 94.7%, respectively (p < 0.0001).Conclusions. Because the survival rates of the validation group were almost identical to the test group, this score can be considered valid and reproducible.

Original languageEnglish (US)
Pages (from-to)802-806
Number of pages5
JournalStrahlentherapie und Onkologie
Volume188
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Spinal Cord Compression
Prostatic Neoplasms
Survival Rate
Survival
Neoplasm Metastasis
Radiotherapy
Multivariate Analysis
Bone and Bones
Neoplasms
Spine

Keywords

  • Metastatic spinal cord compression
  • Prognostic score
  • Prostate cancer
  • Radiation therapy
  • Survival

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

Rades, D., Douglas, S., Veninga, T., Bajrovic, A., Stalpers, L. J. A., Hoskin, P. J., ... Schild, S. E. (2012). A survival score for patients with metastatic spinal cord compression from prostate cancer. Strahlentherapie und Onkologie, 188(9), 802-806. https://doi.org/10.1007/s00066-012-0106-3

A survival score for patients with metastatic spinal cord compression from prostate cancer. / Rades, D.; Douglas, S.; Veninga, T.; Bajrovic, A.; Stalpers, L. J A; Hoskin, P. J.; Rudat, V.; Schild, S. E.

In: Strahlentherapie und Onkologie, Vol. 188, No. 9, 09.2012, p. 802-806.

Research output: Contribution to journalArticle

Rades, D, Douglas, S, Veninga, T, Bajrovic, A, Stalpers, LJA, Hoskin, PJ, Rudat, V & Schild, SE 2012, 'A survival score for patients with metastatic spinal cord compression from prostate cancer', Strahlentherapie und Onkologie, vol. 188, no. 9, pp. 802-806. https://doi.org/10.1007/s00066-012-0106-3
Rades, D. ; Douglas, S. ; Veninga, T. ; Bajrovic, A. ; Stalpers, L. J A ; Hoskin, P. J. ; Rudat, V. ; Schild, S. E. / A survival score for patients with metastatic spinal cord compression from prostate cancer. In: Strahlentherapie und Onkologie. 2012 ; Vol. 188, No. 9. pp. 802-806.
@article{511cd6bcb69b46bdb4a856fd1d642aa6,
title = "A survival score for patients with metastatic spinal cord compression from prostate cancer",
abstract = "Background. This study aimed to develop and validate a survival scoring system for patients with metastatic spinal cord compression (MSCC) from prostate cancer.Patients and methods. Of 436 patients, 218 patients were assigned to the test group and 218 patients to the validation group. Eight potential prognostic factors (age, performance status, number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, time developing motor deficits) plus the fractionation regimen were retrospectively investigated for associations with survival. Factors significant in the multivariate analysis were included in the survival score. The score for each significant prognostic factor was determined by dividing the 6-month survival rate ({\%}) by 10. The total score represented the sum of the scores for each factor. The prognostic groups of the test group were compared to the validation group.Results. In the multivariate analysis of the test group, performance status, ambulatory status, other bone metastases, visceral metastases, and interval from cancer diagnosis to radiotherapy were significantly associated with survival. Total scores including these factors were 20, 21, 22, 24, 26, 28, 29, 30, 31, 32, 33, 35, 37, or 39 points. In the test group, the 6-month survival rates were 6.5{\%} for 20-24 points, 44.6{\%} for 26-33 points, and 95.8{\%} for 35-39 points (p < 0.0001). In the validation group, the 6-month survival rates were 7.4{\%}, 45.4{\%}, and 94.7{\%}, respectively (p < 0.0001).Conclusions. Because the survival rates of the validation group were almost identical to the test group, this score can be considered valid and reproducible.",
keywords = "Metastatic spinal cord compression, Prognostic score, Prostate cancer, Radiation therapy, Survival",
author = "D. Rades and S. Douglas and T. Veninga and A. Bajrovic and Stalpers, {L. J A} and Hoskin, {P. J.} and V. Rudat and Schild, {S. E.}",
year = "2012",
month = "9",
doi = "10.1007/s00066-012-0106-3",
language = "English (US)",
volume = "188",
pages = "802--806",
journal = "Strahlentherapie und Onkologie : Organ der Deutschen R{\"o}ntgengesellschaft ... [et al]",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "9",

}

TY - JOUR

T1 - A survival score for patients with metastatic spinal cord compression from prostate cancer

AU - Rades, D.

AU - Douglas, S.

AU - Veninga, T.

AU - Bajrovic, A.

AU - Stalpers, L. J A

AU - Hoskin, P. J.

AU - Rudat, V.

AU - Schild, S. E.

PY - 2012/9

Y1 - 2012/9

N2 - Background. This study aimed to develop and validate a survival scoring system for patients with metastatic spinal cord compression (MSCC) from prostate cancer.Patients and methods. Of 436 patients, 218 patients were assigned to the test group and 218 patients to the validation group. Eight potential prognostic factors (age, performance status, number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, time developing motor deficits) plus the fractionation regimen were retrospectively investigated for associations with survival. Factors significant in the multivariate analysis were included in the survival score. The score for each significant prognostic factor was determined by dividing the 6-month survival rate (%) by 10. The total score represented the sum of the scores for each factor. The prognostic groups of the test group were compared to the validation group.Results. In the multivariate analysis of the test group, performance status, ambulatory status, other bone metastases, visceral metastases, and interval from cancer diagnosis to radiotherapy were significantly associated with survival. Total scores including these factors were 20, 21, 22, 24, 26, 28, 29, 30, 31, 32, 33, 35, 37, or 39 points. In the test group, the 6-month survival rates were 6.5% for 20-24 points, 44.6% for 26-33 points, and 95.8% for 35-39 points (p < 0.0001). In the validation group, the 6-month survival rates were 7.4%, 45.4%, and 94.7%, respectively (p < 0.0001).Conclusions. Because the survival rates of the validation group were almost identical to the test group, this score can be considered valid and reproducible.

AB - Background. This study aimed to develop and validate a survival scoring system for patients with metastatic spinal cord compression (MSCC) from prostate cancer.Patients and methods. Of 436 patients, 218 patients were assigned to the test group and 218 patients to the validation group. Eight potential prognostic factors (age, performance status, number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, time developing motor deficits) plus the fractionation regimen were retrospectively investigated for associations with survival. Factors significant in the multivariate analysis were included in the survival score. The score for each significant prognostic factor was determined by dividing the 6-month survival rate (%) by 10. The total score represented the sum of the scores for each factor. The prognostic groups of the test group were compared to the validation group.Results. In the multivariate analysis of the test group, performance status, ambulatory status, other bone metastases, visceral metastases, and interval from cancer diagnosis to radiotherapy were significantly associated with survival. Total scores including these factors were 20, 21, 22, 24, 26, 28, 29, 30, 31, 32, 33, 35, 37, or 39 points. In the test group, the 6-month survival rates were 6.5% for 20-24 points, 44.6% for 26-33 points, and 95.8% for 35-39 points (p < 0.0001). In the validation group, the 6-month survival rates were 7.4%, 45.4%, and 94.7%, respectively (p < 0.0001).Conclusions. Because the survival rates of the validation group were almost identical to the test group, this score can be considered valid and reproducible.

KW - Metastatic spinal cord compression

KW - Prognostic score

KW - Prostate cancer

KW - Radiation therapy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84866646508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866646508&partnerID=8YFLogxK

U2 - 10.1007/s00066-012-0106-3

DO - 10.1007/s00066-012-0106-3

M3 - Article

C2 - 22526228

AN - SCOPUS:84866646508

VL - 188

SP - 802

EP - 806

JO - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

JF - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

SN - 0179-7158

IS - 9

ER -